XENETIC BIOSCIENCES (UK) LIMITED

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  —

  Not reported

• Net assets

  -31%

  £10,034,123 → £6,920,697

• Employees

  —

  Not reported

• Operating profit

  -15,535.9%

  £20,170 → -£3,113,426

• Profit before tax

  -15,535.9%

  £20,170 → -£3,113,426

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. XENETIC BIOSCIENCES (UK) LIMITED 2014-06-24 → present
2. XENETIC BIOSCIENCES (UK) PLC 2014-06-24 → 2014-06-24
3. XENETIC BIOSCIENCES PLC 2011-09-05 → 2014-06-24
4. LIPOXEN PLC 2006-01-16 → 2011-09-05
5. GREENCHIP INVESTMENTS PLC 1999-07-28 → 2006-01-16
6. INFANTCARE PLC 1996-09-04 → 1999-07-28
7. THOMPSON TURNBURY PLC 1996-06-12 → 1996-09-04

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

F. W. Smith, Riches & Co.

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“As a wholly owned-subsidiary of its US-listed parent company, Xenetic Biosciences, Inc (XBIO), the Company ultimately depends upon the Group for funding. Consequently, the directors have received a letter of comfort from XBIO confirming XBIO's intention to provide such level of financial support to the Company for a period of at least 12 months from the date of this Report such that the Company will be able to meet its obligations as they fall due.”

Group structure

1. XENETIC BIOSCIENCES (UK) LIMITED · parent
   1. Lipoxen Technologies Limited 100% · England and Wales · research into drug delivery systems
   2. SymbioTec GmbH 100% · Germany · early stage clinical trials
   3. Xenetic Bioscience Incorporated 100% · United States of America · fund its operations

Significant events

• “Notwithstanding that the Company's UK subsidiary, Lipoxen Technologies Limited, is currently profitable and cash-generative, since its inception, the business of the Group has incurred, and continues to incur, significant losses from operations.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.